Association of State Medicaid Income Eligibility Limits and Long-Term Survival After Cancer Diagnosis in the United States.


Journal

JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685

Informations de publication

Date de publication:
06 2022
Historique:
pubmed: 8 1 2022
medline: 15 6 2022
entrez: 7 1 2022
Statut: ppublish

Résumé

To examine the association between historic state Medicaid income eligibility limits and long-term survival among patients with cancer. 1,449,144 adults age 18-64 years newly diagnosed with 19 common cancers between 2010 and 2013 were identified from the National Cancer Database. States' Medicaid income eligibility limits were categorized as ≤ 50%, 51%-137%, and ≥ 138% of federal poverty level (FPL). Survival time was measured from diagnosis date through December 31, 2017, for up to an 8-year follow-up. Multivariable Cox proportional hazards models with age as time scale were used to assess associations of eligibility limits and stage-specific survival, adjusting for the effects of sex, metropolitan statistical area, comorbidities, year of diagnosis, facility type and volume, and state. Among patients with newly diagnosed cancer age 18-64 years, patients living in states with lower Medicaid income eligibility limits had worse survival for most cancers in both early and late stages, compared with those living in states with Medicaid income eligibility limits ≥ 138% FPL. A dose-response relationship was observed for most cancers with lower income limits associated with worse survival (13 of 17 cancers evaluated for early-stage cancers, and 11 of 17 cancers evaluated for late-stage cancers, and leukemia and brain tumors with Lower Medicaid income eligibility limits were associated with worse long-term survival within stage; increasing Medicaid income eligibility may improve survival after cancer diagnosis.

Identifiants

pubmed: 34995127
doi: 10.1200/OP.21.00631
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e988-e999

Auteurs

Jingxuan Zhao (J)

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia.

Xuesong Han (X)

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia.

Leticia Nogueira (L)

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia.

Noorie Hyun (N)

Division of Biostatistics, Kaiser Permanente Washington Health Research Institute, Seattle, WA.

Ahmedin Jemal (A)

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia.

K Robin Yabroff (KR)

Surveillance and Health Equity Science, American Cancer Society, Atlanta, Georgia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH